Promising results of new Alzheimers Drug
Finally some good news about a clinical trial, and even one that Boston University Alzheimer’s Disease Center was a site for! The BAN2401 study (sponsored by Eisai and Biogen) topline results came out, indicating a significant outcome. This was a Phase 2 study so up next will be Phase 3.
Click here for full Press Release